Previous 10 | Next 10 |
NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development an...
2023-08-13 17:35:24 ET Major earnings expected after the bell on Monday include: Suncor Energy ( SU ) Canoo ( GOEV ) Sachem Capital Corp. ( SACH ) Astra Space ( ASTR ) Ayro ( AYRO ) For further details see: Notable earnings after Monday's ...
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain PR Newswire NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian , a world leader in pain and D-Cyc...
NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023 PR Newswire RADNOR, Pa. , Aug. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical comp...
NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference PR Newswire RADNOR, Pa. , June 20, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biop...
NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering PR Newswire RADNOR, Pa. , June 9, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company...
NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering PR Newswire RADNOR, Pa. , June 6, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today ann...
NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023 PR Newswire RADNOR, Pa. , June 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biophar...
2023-05-16 13:33:07 ET NRx Pharmaceuticals, Inc. (NRXP) Q1 2023 Earnings Call May 16, 2023 8:30 AM ET Company Participants Suzanne Messere - Investor Relations, Stern Stephen Willard - Chief Executive Officer and Director Seth Van Voorhees - Chief Financial Offic...
2023-05-16 06:51:24 ET NRx Pharmaceuticals press release ( NASDAQ: NRXP ): Q1 GAAP EPS of -$0.16. Ended quarter with $16.5 million in cash and cash equivalents For further details see: NRx Pharmaceuticals GAAP EPS of -$0.16
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...